Pharmerica (CNSX:PMC) and 3737 (CNSX:RFR) are both basic materials companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.
Profitability
This table compares Pharmerica and 3737's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Pharmerica | N/A | N/A | N/A |
3737 | N/A | N/A | N/A |
Earnings & Valuation
This table compares Pharmerica and 3737's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Pharmerica | N/A | N/A | N/A | N/A | N/A |
3737 | N/A | N/A | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Pharmerica and 3737, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Pharmerica | 0 | 0 | 0 | 0 | N/A |
3737 | 0 | 0 | 1 | 0 | 3.00 |
3737 has a consensus price target of $0.12, suggesting a potential upside of ∞.
Summary
3737 beats Pharmerica on 1 of the 1 factors compared between the two stocks.